Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion.
The receptor for urokinase-type plasminogen activator (uPAR) plays an important role in controlling cell migration. uPAR binds urokinase and vitronectin extracellular ligands, and signals in complex with transmembrane receptors such as Formyl-peptide Receptors (FPR)s and integrins. Previous work from this laboratory has shown that synthetic peptides, corresponding to the uPAR(88-92) chemotactic sequence, when carrying the S90P or S90E substitutions, up- or down-regulate cell migration, respectively. To gain mechanistic insights into these opposite cell responses, the functional consequences of S90P and S90E mutations in full-length uPAR were evaluated. First, (HEK)-293 embryonic kidney cells expressing uPAR(S90P) exhibit enhanced FPR activation, increased random and directional cell migration, long-lasting Akt phosphorylation, and increased adhesion to vitronectin, as well as uPAR/vitronectin receptor association. In contrast, the S90E substitution prevents agonist-triggered FPR activation and internalization, decreases binding and adhesion to vitronectin, and inhibits uPAR/vitronectin receptor association. Also, 293/uPAR(S90P) cells appear quite elongated and their cytoskeleton well organized, whereas 293/uPAR(S90E) cells assume a large flattened morphology, with random orientation of actin filaments. Interestingly, when HT1080 cells co-express wild type uPAR with uPAR S90E, the latter behaves as a dominant-negative, impairing uPAR-mediated signaling and reducing cell wound repair as well as lung metastasis in nude mice. In contrast, signaling, wound repair and in vivo lung metastasis of HT1080 cells bearing wild type uPAR are enhanced when they co-express uPAR(S90P). In conclusion, our findings indicate that Ser(90) is a critical residue for uPAR signaling and that the S90P and S90E exert opposite effects on uPAR activities. These findings may be accommodated in a molecular model, in which uPAR(S90E) and uPAR(S90P) are forced into inactive and active forms, respectively, suggesting important implications for the development of novel drugs targeting uPAR function.
Department of Experimental Oncology, National Cancer Institute of Naples, Naples, Italy.
Katia
K
Bifulco
Immacolata
I
Longanesi-Cattani
Paola
P
Franco
Vincenzo
V
Pavone
Pietro
P
Mugione
Gioconda
G
Di Carluccio
Maria Teresa
MT
Masucci
Claudio
C
Arra
Giuseppe
G
Pirozzi
Maria Patrizia
MP
Stoppelli
Maria Vincenza
MV
Carriero
D019943:Amino Acid Substitution; D000818:Animals; D002448:Cell Adhesion / Q000235:genetics; D045744:Cell Line, Tumor / Q000637:transplantation; D002465:Cell Movement / Q000235:genetics; D048430:Cell Shape / Q000235:genetics; D015870:Gene Expression; D057809:HEK293 Cells; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D009361:Neoplasm Invasiveness / Q000235:genetics*; D010766:Phosphorylation; D010957:Plasmids; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism; D044042:Receptors, Formyl Peptide / Q000235:genetics / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction; D014162:Transfection; D019096:Vitronectin / Q000235:genetics / Q000378:metabolism
D039302:Integrin alphaVbeta3; D044042:Receptors, Formyl Peptide; D055293:Receptors, Urokinase Plasminogen Activator; D019096:Vitronectin; D051057:Proto-Oncogene Proteins c-akt